Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


The abstract submission is now open!

Submit your abstract

Abstract submission deadlines 


Date and time

  • Abstract 
  • Trial in Progress
  • Intent to submit LBA

Monday, 28 September 2020 

21:00hrs CEST (Central European Summer Time)

  • Late-breaking abstracts (LBA)

Wednesday, 4 November 2020

21:00hrs CET (Central European Time)

Submission categories

  • Biomarker development
  • Tumour biology
  • Cell therapy
  • Therapeutic development
  • Clinical practice
  • Miscellaneous
  • SARS-CoV-2 and cancer

Late-breaking abstracts (LBA) 

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.  

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 28 September 2020 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO Immuno-Oncology Congress 2020.  

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on of Monday, 28 September 2020.   

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by Wednesday, 4 November 2020. 

Trial in progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2020.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

  • Background
  • Trial design


  • Recruitment must have already begun or have been completed by the abstract submission deadline of 28 September 2020.
  • Abstracts including results or preliminary data will be rejected.
  • Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
  • Encore TiP abstracts will be rejected.

Trial in Progress (TiP) abstracts will be reviewed by the ESMO Immuno-Oncology Congress 2020 Scientific Committee and considered on the merits of the scientific and clinical rationale of the trial.

Presentation options for accepted abstracts 

The ESMO Immuno-Oncology Congress 2020 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

  • Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
  • Poster – Display sessions for review, discussion and questions. Posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work.

All accepted abstracts, including Late-breaking, will be published online only in the ESMO Immuno-Oncology Congress 2020 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Travel Grants

A restricted number of travel grants to the ESMO Immuno-Oncology Congress 2020 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the ESMO Immuno-Oncology Congress 2020 Scientific Committee on a competitive basis from among the accepted abstracts.

More information can be found in the Abstract regulations.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings